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Monocytes differentiate into macrophages, which deactivate
invading pathogens. Macrophages can be resistant to cell death
mechanisms in some situations, and the mechanisms involved
are not clear. Here, using mouse immune cells, we investigated
whether the differentiation ofmacrophages affects their suscep-
tibility to cell death by the ripoptosome/necrosome pathways.
We show that treatment of macrophages with a mimetic of sec-
ond mitochondrial activator of caspases (SMAC) resulted in
ripoptosome-driven cell death that specifically depended on
tumor necrosis factor  (TNF) expression and the receptor-
interacting serine/threonine protein kinase 1 (RipK1)–RipK3–
caspase-8 interaction in activated and cycling macrophages.
Differentiation of macrophages increased the expression of
pro-inflammatory cytokines but reduced RipK1-dependent
cell death and theRipK3–caspase-8 interaction. The expression
of the anti-apoptotic mediators, X-linked inhibitor of apoptosis
protein (XIAP) and caspase-like apoptosis regulatory protein
(cFLIPL), also increased in differentiated macrophages, which
inhibited caspase activation. The resistance to cell death was
abrogated in XIAP-deficient macrophages. However, even in
the presence of increased XIAP expression, inhibition of the
mitogen-activated protein kinase (MAPK) p38 andMAPK-acti-
vated protein kinase 2 (MK2) made differentiated macrophages
susceptible to cell death. These results suggest that the p38/
MK2 pathway overrides apoptosis inhibition by XIAP and that
acquisition of resistance to cell death by increased expression of
XIAP and cFLIPL may allow inflammatory macrophages to par-
ticipate in pathogen control for a longer duration.
Cell death plays an integral role in maintaining tissue home-
ostasis during normal development as well as during infection.
Whereas apoptosis is vital for embryonic development and
elimination of self-reactive immune cells (1), cell death induced
by inflammasome and necrosome signaling is highly inflamma-
tory (2, 3). There are various cell death platforms, each with
different mechanisms and consequences for cell signaling
(4–6). Proteins of the receptor-interacting protein kinase fam-
ily, such as RipK1 and RipK3, play key roles in the assembly of
the ripoptosome and necrosome signaling complexes (7, 8).
The tumor necrosis factor (TNF)2 receptor (TNF-R) engage-
ment induces the formation of a cell survival complex that pro-
motes activation of NF-B and MAPKs (9–11). Cellular inhib-
itors of apoptosis proteins (cIAP1/2) maintain RipK1 in this
complex, but the degradation of cIAPs by the secondmitochon-
drial activator of caspases (SMAC) or other unknown mecha-
nisms releases RipK1 from this complex and results in the inter-
action of RipK1 with FADD, RipK3, and caspase-8 to form the
ripoptosome complex (12, 13). When caspase-8 activity is inhib-
ited, RipK1, RipK3, caspase-8, and the pseudokinase MLKL
instead form the necrosome (14–16). During necrosome signal-
ing, RipK3 phosphorylates MLKL, which results in the formation
ofMLKL trimers that relocate to the cellmembrane and cause cell
rupture and release of intracellular DAMPs (17, 18).
Activation of cell death is particularly important in the
immune system, which facilitates the control of pathogens (2,
19). Myeloid cells (neutrophils, monocytes, macrophages, and
dendritic cells) provide the first line of defense against patho-
gens, and these cell types are highly vulnerable to cell death.
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Monocytes represent 10% of the circulating leukocytes in
humanblood (20), whichmaintain homeostasis by replenishing
the pool of tissue macrophages in steady state. Macrophages
promote inflammatory responses (21) and also play an impor-
tant role in resolving inflammation by remodeling and repair-
ing tissues through efferocytosis (22). Different types of macro-
phages exist in different anatomical compartments (microglia,
osteoclasts, Kupffer cells, alveolar macrophages, etc.) (22).
Whereas most tissue macrophages are derived from blood cir-
culating monocytes, embryonic precursors can also be the
source of tissue macrophages, which undergo self-replication
and are not dependent on replenishment by circulating mono-
cytes (23, 24). Unlike monocytes, macrophages have a long life
span, ranging from months to years (25).
Monocytes circulate in the blood for a few days before differ-
entiating into macrophages or dendritic cells in the tissues in
response to chemokines or cytokines (26). Upon differentia-
tion, macrophages acquire resistance to cell death, but the
mechanism has been unclear (27). We have evaluated the
impact of macrophage differentiation on their susceptibility to
cell death by the ripoptosome and necrosome pathway. Our
results indicate that macrophage differentiation results in
increased expression of endogenous inhibitors of cell death,
cFLIPL and XIAP, which promotes resistance to cell death by
the ripoptosome pathway.
Results
Differentiatedmacrophages are resistant to SMAC
mimetic–induced cell death
In the course of our earlier work investigating the toxicity of
SMACmimetic compounds, we made an unexpected observa-
tion that macrophages showed different sensitivity, depending
on their differentiation status. To further tease out the relation-
ship ofmacrophage differentiationwith cell death signaling, we
purified monocytes from bone marrow (CD11bLy6CF4/
80) and differentiated them into macrophages for varying
periods (CD11bLy-6CF4/80) with M-CSF (Fig. 1A). The
expression of CD11b increased upon differentiation with
M-CSF (Fig. 1B), and there was a slight increase in the number
of cells obtained with prolonged differentiation of cells (Fig.
1C). Cells that were harvested at day 12 of differentiation pro-
duced increased levels of pro-inflammatory cytokines following
LPS stimulation, compared with cells harvested at day 5 of dif-
ferentiation (Fig. 1D). Macrophages isolated at day 5 of differ-
entiation showed slightly more proliferative potential com-
pared with day 12 macrophages, as revealed by the expression
of Ki67 (Fig. 1, E and F).
We evaluated the consequences of macrophage differentia-
tion on their susceptibility to cell death by the SMACmimetic,
birinapant (BP). SMAC mimetics can induce cell death by the
various RipK1-dependent pathways (12, 28).Macrophages har-
vested at later time intervals of differentiation progressively
acquired resistance to BP-induced cell death (Fig. 1, G–I). Cell
death was also inhibited by necrostatin-1 (Nec-1) (Fig. 1J),
which inhibits the kinase activity of RipK1 (29). Inhibition of
the kinase activity of RipK3, which also participates in ripopto-
some signaling, byGSK872 did not inhibit cell death induced by
BP (Fig. 1J). Similar results were obtained when cell death was
induced by a different SMAC mimetic, BV6 (Fig. S1). These
results suggest that macrophages isolated at day 12 of differen-
tiation are resistant to ripoptosome-dependent cell death.
BP-induced cell death of earlymacrophages occurs through
ripoptosome signaling
We have recently reported a knock-in mouse model where a
conserved lysine in the kinase subdomain II of RipK1 was
mutated to alanine (K45A), resulting in a kinase-inactive
mutant of RipK1. The K45A mutation of RipK1 results in
impairment in control of S. enterica Typhimurium infection in
vivo, which correlated with decreased macrophage cell death,
decreased reactive oxygen species production, and decreased
activation of caspase-8 (30).We therefore evaluated the impact
of the K45A mutation of RipK1 on BP-induced cell death. Our
results indicate that Lys to Ala mutation at amino acid 45 of
RipK1 abolished BP-induced cell death (Fig. 2A). Cell deathwas
also dependent on RipK3 (Fig. 2B), and there was a modest
impact of the adaptor protein Trif, but not Myd88 or Ifnar1
(Fig. 2, C–E). The Lys-45 activity of RipK1 was required for
activation of caspase-8/9/3/7 following treatment with BP (Fig.
2, F–H). BP-induced cell death was highly dependent on Tnfr1
and Tnf, but not on Tnfr2 signaling (Fig. 2, I and J). In the
absence of Tnf, phosphorylation of RipK1 (upper band) and
MK2 was reduced (Fig. 2, K and L).
Impaired ripoptosome signaling in differentiated
macrophages
Because expression of TNF was required for BP-induced
cell death (Fig. 2J), we measured the mRNA (Fig. 3A) and pro-
tein (Fig. 3B) levels of TNF in macrophages following treat-
ment with BP. Our results revealed similar levels of TNF in
macrophages isolated at day 5 or day 12 of differentiation.
These results indicate that the impairment in day 12 macro-
phages to cell death induced by BP treatment is not related to
TNF expression. Macrophages isolated at day 12 of differen-
tiation displayed poor phosphorylation of RipK1 following
BP treatment in contrast to day 5 macrophages (Fig. 3, C and D).
BP treatment did not induce any phosphorylation of RipK3 in
day 5 or day 12 macrophages. Because ripoptosome-induced
cell death is mediated by the activation of caspase-8, we evalu-
ated the expression of caspase-8 in macrophages following
treatment with BP. There was no difference in the basal level of
caspase-8 in day 5 versus day 12 macrophages; however, active
caspase-8 was detected only in BP-treated day 5 macrophages
(Fig. 3E). Similar results were obtained when the activity
of caspase-8 was measured by a colorimetric bioassay (Fig.
3F). Immunoprecipitation of caspase-8 revealed a RipK3–
caspase-8 interaction in day 5 macrophages treated with BP,
but not in day 12 macrophages (Fig. 3G). Taken together, these
results indicate that continued differentiation of macrophages
to day 12 results in impairment in ripoptosome signaling–
induced cell death, without any impact on TNF expression.
We evaluated whether concurrent engagement of TLR4 in
day 12macrophages would overcome their resistance to BP-in-
duced cell death. Our results indicate that LPS  BP induces
cell death in macrophages that operates through an atypical
Macrophage differentiation inhibits ripoptosome signaling
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ripoptosomepathway that is less dependent on the kinase activ-
ity of RipK1, but more shifted toward RipK3 dependence, and
day 12 macrophages were still resistant to LPS  BP–induced
cell death (Fig. S2, A–I).
Differentiatedmacrophages develop partial resistance to
necrosome signaling
Considering the promiscuous interaction of RipK1 and
RipK3 in the ripoptosome and necrosome signaling complexes,
we sought to determine whether differentiation of macro-
phages influenced their susceptibility to cell death by the necro-
some pathway. Inhibition of caspases with the pan-caspase
inhibitor Z-VAD did not rescue BP-induced cell death; rather,
themechanismof cell death shifted to Ifnar1 andRipK3-depen-
dent necroptosis, which was rescued by inhibitors against
RipK1 and RipK3 (Fig. 4, A and B). Cell death was significantly
dependent on Tnfr1 but not Tnfr2 signaling (Fig. 4B). Macro-
phages isolated at day 12 of differentiation displayed moderate
but significant resistance to cell death induced by BPZ-VAD
(Fig. 4C), although the potency of this resistance was not as
Figure1.Differentiationofmacrophagesresults in resistancetoripoptosome-inducedcelldeath.Monocyteswere isolated fromthebonemarrowofC57BL/6J
(WT)miceanddifferentiated intomacrophageswithM-CSF, and theexpressionof Ly-6C, F4/80, andCD11bwasevaluatedby flowcytometry (AandB). Cell yield after
5 or 12 days of culturewithM-CSFwas enumerated (C). Day 5 or day 12macrophageswere stimulatedwith LPS (100 ng/ml), and the expression of various cytokines
in the supernatants collectedat 24hwasquantitatedbyELISA (D). Intracellular staining for Ki67wasenumerated in cells collectedatday5andday12post-treatment
withM-CSF(EandF).Differentiatingmacrophageswereharvestedatvarioustimeintervalspost-treatmentwithM-CSFandincubatedwithBP(10M) in96-wellplates,
and cell viability was evaluated 24 h later by MTT uptake (G) or at 12 h by PI/Hoechst staining (H). Cell death was also evaluated at various time intervals post-BP
treatmentbyMTTassay (I). InhibitorsagainstRipK1(Nec-1,10M)orRipK3(GSK872,10M)wereaddedtodeterminethemechanismofBP-inducedcelldeath (J). Each
experimentwas repeated three timeswith triplicate samples. *, p 0.05; **, p 0.01; ***, p 0.001; ****, p 0.0001. Error bars, S.E.
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strong as was observed with BP alone. Day 12 macrophages
displayed significant resistance to necroptosis induced by
TNF  Z-VAD (Fig. 4D). Necroptosis was also induced in
macrophages by treatment with LPS  Z-VAD, which
depended on Ifnar1 and RipK3 (Fig. 4, E and F). Here again, day
12 macrophages displayed a small but significant resistance to
cell death induced by LPS  Z-VAD (Fig. 4G). Differentiation
of macrophages resulted in a progressive increase in resistance
to necroptosis, although the potency of this resistance was not
as great as that observed in response to ripoptosome signaling
(Fig. 4H). Activation of necroptosis by LPS  Z-VAD resulted
in phosphorylation of RipK1 andRipK3 in both day 5 andday 12
Figure 2. Earlymacrophages undergo cell death through a typical ripoptosome pathway. Bonemarrow–derivedmacrophages were harvested at day 5
post-differentiation with M-CSF and treated with BP (10 M) (A–L). Cell death was evaluated at 24 h post-treatment with BP by MTT uptake (A–E, I, and J).
Macrophages were harvested at 4 h post-treatment with BP, and the activity of caspase-8/9/3/7 was evaluated by cleavage of specific substrates and
corresponding chemiluminescence detection (F–H). Cell extracts were isolated at various time intervals after BP treatment of WT and TNF/macrophages,
and the activation of RipK1, MK2, and p38 MAPK was evaluated by Western blotting (K). Densitometric analysis of Western blots was performed (L). Each
experiment was repeated three times with triplicate samples. *, p 0.05; ***, p 0.001; ****, p 0.0001. Error bars, S.E.
Macrophage differentiation inhibits ripoptosome signaling
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macrophages (Fig. 4, I and J). As expected, treatment with BP
resulted in degradation of cIAP1/2 (Fig. 4I).
Increased expression of XIAP causes resistance of
differentiatedmacrophages to cell death
Having observed increased cytokine expression by day 12
macrophages in response to LPS treatment (Fig. 1D), we con-
sidered the possibility that inhibition of NF-B signaling might
abrogate the resistance of day 12 macrophages to cell death by
the ripoptosome pathway. Treating day 5 macrophages with
low levels of IKK inhibitor did not significantly impact BP-in-
duced cell death (Fig. 5A), whereas the resistance of day 12
macrophages to cell deathwas abrogated (Fig. 5B). Other inhib-
itors of NF-B showed similar results (Fig. S3,A and B). Day 12
macrophages isolated fromNIK-deficientmicewere still resist-
ant to BP-induced cell death (Fig. 5C), demonstrating no
involvement of the noncanonical NF-B pathway. Treatment
with BP resulted in rapid degradation of cIAP1/2 in macro-
Figure3.Macrophagedifferentiation results in impairment inRipK1phosphorylationand caspase-8 activation.Macrophages fromWTmicewere harvested
at day 5 or day 12 post-differentiation with M-CSF and treated with BP (10M) for various time intervals, and the expression of TNFwas evaluated at various time
intervalsbyquantitativeRT-PCR(A)orbythesensitivebioassay (B).Cellextractswere isolated,andWesternblotting (C) anddensitometricanalysis (D)wereperformed.
Activation of caspase-8was determinedbyWestern blotting of cell extracts at 4 h after BP treatment (E). Activity of caspase-8was evaluatedby cleavageof substrate
andchemiluminescencedetection (F).Cell extractswerecollected frommacrophages (controlorBP-treated for4h), caspase-8was immunoprecipitated,andthe interacting
proteinswere revealedbyWesternblottingof immunoprecipitates (G).Western blottingwas also performed in nonimmunoprecipitated cell extracts. Each experiment
was repeated three timeswith triplicate samples. ***, p 0.001.Western blotting of actin is reused in C andD and in Fig. 5D. RLU, relative light units. Error bars, S.E.
Macrophage differentiation inhibits ripoptosome signaling
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phages as expected, but there was no difference in this degra-
dation between day 5 and day 12 macrophages (Fig. 5D). Inter-
estingly, the expression of the two endogenous inhibitors of the
ripoptosome/necrosome pathways, XIAP and cFLIPL, was ele-
vated in day 12 macrophages following treatment with BP (Fig.
5, D–F) or LPS  BP (Fig. S3, C–E). The resistance of day
12 macrophages to BP-induced cell death was abrogated in
XIAP-deficient macrophages (Fig. 5G), which correlated with
increased TNF expression and caspase-8 activation (Fig. 5, H
and I). XIAP did not appear to regulate cFLIPL expression or
RipK1 phosphorylation in day 12 macrophages; however, the
phosphorylation of MK2 was enhanced in XIAP-deficient
macrophages (Fig. 5, J and K). Although the deficiency of XIAP
in day 12macrophages resulted in cell death following BP treat-
ment, the mechanism of cell death was still ripoptosome-de-
pendent, as it was rescued by Nec-1, not GSK872 (Fig. 5L).
XIAPhadno impact onBPZ-VAD–induced cell death by the
necroptotic pathway (Fig. 5M). Taken together, these results
confirm that differentiatedmacrophages express increased lev-
els of XIAP,which promotes their resistance to cell death by the
ripoptosome pathway. Resistance of day 12 macrophages to
LPS  BP–induced cell death was also abrogated in XIAP-de-
ficient macrophages (Fig. S3F).
Inhibition of p38MAPK signaling pathway restores
ripoptosome-induced cell death in differentiated
macrophages
Having observed that TNF-R signaling was required for
ripoptosome-induced cell death and that the phosphorylation
of MK2, the downstream target of p38 MAPK, was reduced in
Figure4.Macrophagedifferentiationresults inapartialresistancetonecrosome-inducedcelldeath.Bonemarrow–derivedmacrophagesweretreatedwithBP
(10M)andZ-VAD(50M) intheabsenceorpresenceofNec-1(10M)orGSK872(5M),andcelldeathwasevaluated24hlaterbyMTTassay(A–C).Macrophageswere
also treatedwithTNF (50ng/ml) (D) or LPS (1ng/ml) (E–H) andZ-VAD (50M) in theabsenceorpresenceofNec-1 (10M), andcell deathwasevaluated24h later by
MTTassay.Westernblotanalysiswasperformedoncell extracts isolatedatvarious time intervalsafter stimulationwithLPSZ-VADorBP (I). Proteinexpression (I)was
quantitatedbydensitometric analysis (J). Eachexperimentwas repeated three timeswith triplicate samples. **,p0.01; ***,p0.001; ****,p0.0001.Errorbars, S.E.
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TNF-deficientmacrophages (Fig. 2,K andL), we evaluated the
role of p38 MAPK signaling in cell death resistance of day 12
macrophages. Our results indicate that prolonged macrophage
differentiation results in reduced phosphorylation of p38
MAPK and MK2 in response to BP treatment (Fig. 6A and Fig.
S4,A andB). Inhibiting p38MAPK abrogates their resistance to
cell death in response to BP (Fig. 6B), with a corresponding loss
of MK2 phosphorylation (Fig. 6C and Fig. S4C) and an increase
in caspase-8 activation (Fig. S4, D and E). There was no impact
of inhibition of p38MAPKon the expression of XIAP or cFLIPL
(Fig. 6C and Fig. S4, F and G). Day 12 macrophages displayed
increased activation of JNK and ERK, which were elevated fur-
ther by inhibition of p38 MAPK (Fig. 6D and Fig. S4, H and I).
Unlike the impact of p38 MAPK (Fig. 6B), inhibition of the
MEK/ERKor JNKpathways did not have any significant impact
on the resistance of day 12 macrophages to BP-induced cell
death (Fig. 6, E–G). Expression of TNF in response to LPS
treatment was significantly reduced in MK2-deficient macro-
phages (Fig. 6H), whereas the opposite results were obtained
following BP treatment (Fig. 6I). MK2 deficiency abrogated the
Figure 5. Macrophage differentiation results in increased expression of XIAPwhich promotes resistance of differentiatedmacrophages to ripopto-
some-induced cell death. Bonemarrow–derivedmacrophages were harvested fromWT (A–C) or NIK/ (C) mice at day 5 or day 12 post-differentiation and
treated with BP (10M) in the presence or absence of NF-B inhibitor (JSH-23, 1M) or Nec-1 (10M) (A and B). Cell death was evaluated at 24 h byMTT assay.
Western blotting (D and E) and corresponding densitometric analysis (F) was performed on cell extracts collected fromWTmacrophages treated with BP for
various time intervals. Bonemarrow–derivedmacrophageswere harvested fromWT and XIAP/mice at day 5 and day 12 post-differentiation, and cell death
was evaluated at 24 h after BP (10M) treatment (G). The level of TNF secreted byWT and XIAP/macrophages was evaluated at 6 h post-BP treatment (H).
Caspase-8 activity was evaluated at 4 h post-BP treatment by chemiluminescence assay (I). Western blotting (J) and corresponding densitometric analysis (K)
were performedon cell extracts collected fromWT and XIAP/macrophages treatedwith BP for various time intervals.WT and XIAP/macrophages (day 12
of differentiation) were treated with BP (L) or BP Z-VAD (M) in the presence or absence of Nec-1 or GSK872, and cell death was evaluated 24 h later by MTT
assay. Each experiment was repeated three times with triplicate samples. *, p 0.05; **, p 0.01; ***, p 0.001; ****, p 0.0001; ns, not significant. Western
blotting of actin shown in D is reused in Fig. 3 (C and E). Error bars, S.E.
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resistance of day 12macrophages to BP-induced cell death (Fig.
6J), which correlated with increased activation of caspase-8
(Fig. 6K and Fig. S4J) and loss of RipK1 phosphorylation (Fig. 6L
and Fig. S4K). Therewas no impact ofMK2on the expression of
XIAP (Fig. 6L). Enhancement in cell death by inhibition of p38
MAPK occurred through the ripoptosome pathway, as it was
inhibited byNec-1, not GSK872, andwas still dependent on the
Lys-45 kinase region of RipK1 (Fig. S4L). Taken together, these
results indicate that activation of the p38MAPK/MK2 pathway
appears to be reduced in differentiated macrophages, yet inhi-
bition of this pathway abrogates the resistance of differentiated
macrophages to ripoptosome-induced cell death.
Activated and proliferatingmacrophages are eliminated by
ripoptosome signaling
Wealso evaluated the impact of ripoptosome andnecrosome
signaling in splenic and peritoneal macrophages. Macrophages
were purified from the peritoneum of naive mice or from mice
that were injectedwith thioglycolate for 5 days. Treatmentwith
BP resulted in modest cell death in peritoneal macrophages
isolated from naive mice (Fig. 7A). In contrast, macrophages
isolated from the peritoneum of thioglycolate injected mice
were highly susceptible to BP-induced cell death (Fig. 7B),
which was rescued only by inhibition of both apoptosis and
necroptosis pathways. These results suggest that activation of
resident macrophages enhances their susceptibility to BP-in-
duced cell death and that the peritoneal macrophages are more
flexible at switching between cell death pathways. Similarly,
splenic macrophages were also susceptible to BP-induced cell
death, which was rescued only after inhibition of both the
apoptosis and necroptosis pathways (Fig. 7C). Staining of
cells with the cell-cycling protein Ki67 revealed that only the
cycling macrophages were susceptible to BP-induced cell
death (Fig. 7D). Various phenotypic and functional subsets
Figure 6. Inhibition of p38 MAPK pathway restores cell death of differentiated macrophages during ripoptosome signaling. Bone marrow–derived
macrophages were harvested fromWTmice at day 5 or day 12 post-differentiation and treated with BP (10 M), and cell extracts were evaluated by Western
blotting (A). Macrophageswere treatedwith BP (10M) and/or p38MAPK inhibitor (ralimetinib, 5M), and cell deathwas evaluated 24 h later byMTT assay (B).
Cellswere treated asdescribed inB, andWesternblot analysiswasperformedoncell extracts at various time intervals (C andD).Macrophageswere also treated
with BP and/or MEK/ERK inhibitor (PD0325901, 20 nM) or JNK inhibitor (SP600125, 20 M), and cell death was evaluated 24 h later by MTT assay (E–G). TNF
secreted in the supernatants of WT andMK2/macrophages stimulated with LPS (1 ng/ml) (H) or BP (10M) (I) was evaluated at 6 h in the supernatants. WT
and MK2/macrophages were treated with BP (10 M), and cell death was evaluated 24 h later (J). Expression of caspase-8 (K), and RipK1 and XIAP (L) was
evaluated by Western blotting of cell extracts at various time intervals after BP treatment. Each experiment was repeated three times with triplicate samples.
*, p 0.05; **, p 0.01; ***, p 0.001; ****, p 0.0001. Error bars, S.E.
Macrophage differentiation inhibits ripoptosome signaling
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of macrophages have been identified that have been catego-
rized as pro-inflammatory or anti-inflammatory (20, 26, 31),
with CD38 being expressed on pro-inflammatory macro-
phages and EGR2 being expressed on anti-inflammatory
macrophages (31). Thus, we investigated the expression of
CD38 and EGR2 on BP-treated macrophages, where we
observed a significant increase in CD38 and decrease in
EGR2 expression, which could be partially blocked by co-
treatment with Z-VAD/GSK872 (Fig. 7D). Based on these
results, we propose that RipK1-mediated cell death pathways
specifically target actively proliferating early macrophages, and
select for survival of more differentiated and pro-inflammatory
macrophage subsets.
Discussion
Monocytes migrate to the blood from the bone marrow on a
continuous basis, and subsequently differentiate into macro-
phages to replenish the pool of tissue macrophages (20).
Macrophages are the central cell type of the innate immune
system that promote the innate immune response and mediate
pathogen control (32–34). Considering that there are multiple
types of macrophages (20, 26), the precise molecular steps and
the relative timing that is required for monocytes to differenti-
ate into macrophages are not clear. Unlike monocytes, macro-
phages have a long life span, ranging frommonths to years (25),
and it is not clear howmacrophages survive for prolonged peri-
ods in the face of ongoing pathogen insults and trauma. We
have evaluated the impact of macrophage differentiation on
their susceptibility to cell death by the ripoptosome and necro-
some pathways. Our results reveal that differentiation of
macrophages results in up-regulation of endogenous inhibitors
of cell death, which promote resistance against ripoptosome
signaling (Fig. 8).
Macrophages undergo dynamic changes in the expression of
various cell surface molecules during differentiation (31). We
observed that as monocytes differentiated into macrophages,
expression of F4/80, a classic macrophage marker (21), was
induced, whereas the expression of Ly6C, a monocyte marker
(35), was diminished. CD11b is another marker of macrophage
differentiation (36) that was increased during differentiation.
The time required for macrophages to undergo differentiation
is not clear, as macrophages have been isolated at various time
intervals (37, 38). Interestingly, extending the differentiation of
macrophages to 14 days resulted in enhanced control of myco-
bacteria (39), which suggests thatmacrophages continue to dif-
ferentiate beyond day 7 of culture. Interestingly, our results
indicate that peritoneal macrophages form naive mice are
resistant to ripoptosome-induced cell death, akin to the 12-day
differentiated macrophages.
Activation of the ripoptosome complex in fibroblasts results
in cell death that depends on TNF, RipK1, and RipK3 (12, 40).
Nec-1 was identified as an inhibitor that binds to the kinase
region of RipK1 and blocks its function (29) and inhibits ripop-
Figure 7. Activated and cyclingmacrophages are eliminatedby ripoptosome signaling. Peritonealmacrophages fromnaive (A) or thioglycolate-injected
(B)micewere treatedwith BP and/orNec-1 (10M), GSK872 (5M), andZ-VAD (10M). Cell deathwas evaluated 24h later byMTT assay. Spleen cells fromnaive
mice (C and D) were incubated with BP (10 M) and various inhibitors as mentioned above. After 24 h, cells were stained with antibodies against F4/80, CD3,
CD19, and the zombie yellow viability dye, and sampleswere acquired using a high-throughput port by flow cytometry to ensure acquisition of 180l of each
sample. The absolute number of acquired live cells or gated macrophages in 180 l for each sample was determined (C). Cells were also stained for Ki67
(intracellular), CD38, and EGR2using the labeled antibodies, and the impact of BP and various inhibitors on F4/80macrophageswas evaluated (D). Results are
pooled from at least three experiments. *, p 0.05; **, p 0.01; ***, p 0.001; ****, p 0.0001. Error bars, S.E.
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tosome-induced cell death (41). Our results reveal a hierarchi-
cal role for various mediators in BP-induced cell death. TNF
and the Lys-45 kinase activity of RipK1 had the highest impact
on cell death, RipK3 had a moderate impact, and TRIF had a
small impact. The specific mechanism through which RipK1
kinase promotes the formation of the ripoptosome is not very
clear. Interaction of RipK1, RipK3, and caspase-8 appears to be
required for ripoptotosome-induced cell death in fibroblasts,
and our results indicate that this interaction is impaired in day
12 macrophages. Interestingly, we observed that the kinase
activity of RipK1 promotes the activation of caspase-9 and
caspase-3 in addition to the activation of caspase-8. Whereas
activation of caspase-8 would result in downstream activation
of caspase-3, the mechanism through which caspase-9 activa-
tion is influenced by RipK1 is not clear.
RipK3 participates in both ripoptosome and necrosome
pathways; however, the impact of macrophage differentiation
was noticeablemainly in ripoptosome signaling. Because ripop-
tosome-induced cell death depends on active caspase-8, inhibi-
tion of this caspase by increased expression of XIAP endows
macrophages with a mechanism to resist cell death. On the
other hand, necroptosis is induced only when caspases are
inhibited (6); enhancing the expression of XIAP may not have
much impact. Because XIAP does not appear to impact necro-
some signaling, it is conceivable that the marginal resistance
of differentiated macrophages to necrosome signaling may be
related to increased cFLIPL expression.
IAPs act as endogenous inhibitors of cell death (42), and can-
cer cells often express high levels of IAPs (43–45). We have
previously reported that SMAC mimetics induce rapid degra-
dation of cIAP1/2 but not XIAP in macrophages (28). Our
results indicate that the degradation of cIAP1/2 by SMAC
mimetics was similar in day 5 and day 12 macrophages, ruling
out the role of cIAP1/2 in the resistance of day 12macrophages
to cell death. On the other hand, the expression of XIAP was
higher in day 12macrophages, andXIAP inhibits caspase-3 and
caspase-7 (46). XIAP has been previously reported to inhibit
TNF and RipK3-dependent cell death and inflammasome sig-
naling (47). Whereas various SMAC mimetics target IAPs for
degradation, BP induces degradation of cIAP1/2, but not XIAP
(48, 49). Lack of any impact of BP on XIAP levels therefore
makes XIAP available to inhibit cell death in differentiated
macrophages.
In addition to increased expression of XIAP, differentiated
macrophages also expressed increased levels of cFLIPL,which is
a caspase-8 homologue that lacks key residues necessary for
protease activity (50). Whereas cFLIPL functions solely as an
inhibitor of caspase-8 through competition for binding sites,
cFLIPL can act as an activator of caspase-8 by forming a het-
erodimeric complex with caspase-8, with substrate specificity
that is similar to that of caspase-8 homodimers (51). In the case
of ripoptosome signaling, cFLIPL has been shown to inhibit cell
death, whereas the short isoform of cFLIPL promotes ripopto-
some signaling (40). We have failed to detect the expression of
Figure 8. Differentiation of monocytes promotes resistance to ripoptosome signaling. As monocytes differentiate to macrophages, the expression of
XIAP increases, which promotes resistance to cell death induced by ripoptosome signaling. In addition to XIAP, the p38 MAPK/MK2 pathway also promotes
resistance to ripoptosome-induced cell death. Resistance to cell death in highly differentiatedmacrophages could promote their survival during infection and
release of inflammatory cytokines for longer periods.
Macrophage differentiation inhibits ripoptosome signaling
11922 J. Biol. Chem. (2018) 293(30) 11913–11927
 at Copenhagen U
niversity Library on A
ugust 31, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
short isoform of cFLIPL in macrophages. In our experiments, if
increased expression of cFLIPL were responsible for the resis-
tance of differentiated macrophages to ripoptosome-induced
cell death, then XIAP deficiency may not have had a major
impact in abrogating this resistance.
NF-B signaling promotes resistance against TNF-induced
cell death (52, 53), and our results indicate thatNF-B signaling
is involved in promoting the resistance of day 12 macrophages
to ripoptosome-induced cell death. Various studies have shown
that cIAPs have divergent impact on NF-B signaling (12, 54).
In steady state, a cIAP1/2–TRAF2–TRAF3 complex regulates
noncanonicalNF-B through constitutive Lys-48–linked ubiq-
uitination and proteasomal degradation of NIK, a member of
the MAP3 kinase family (55). Degradation of cIAPs by SMAC
mimetics results in stabilization of NIK and activation of the
noncanonical NF-B pathway (56). Our results with NIK-defi-
cient macrophages did not reveal any impact of NIK on SMAC
mimetic–induced cell death, suggesting that this pathway is not
involved in the resistance of day 12macrophages to cell death. It
has also been shown that Lys-63–linked ubiquitination of
RipK1 by cIAPs promotes activation of the canonical NF-B
pathway (12, 54), and degradation of cIAPs by SMACmimetics
may inhibit this pathway and favor cell death. In our experi-
ments, the degradation of cIAPs by a SMACmimetic was sim-
ilar in day 5 and day 12 macrophages, which excludes the pos-
sibility that resistance ofmacrophages to cell death is due to the
impact of cIAPs onNF-B signaling. XIAP has also been shown
to promote NF-B signaling (57), and this may be another ave-
nue through which increased expression of XIAP in day 12
macrophages promotes resistance to cell death.
During TLR signaling, activation of the p38 MAPK/MK2
pathway promotes the stabilization of TNF expression (58). In
contrast, during ripoptosome signaling in myeloid leukemia
cells, p38 MAPK has been shown to inhibit TNF expression,
and inhibition of MK2 results in enhanced cell death of leuke-
mia cells (59). It was subsequently shown thatMK2mediates an
inhibitory phosphorylation of RipK1, which restricts ripopto-
some-induced cell death (60–62). Our results indicate that the
phosphorylation of RipK1 in macrophages depends on MK2,
and inhibition ofMK2 results in augmentation of ripoptosome-
induced cell death, particularly on day 12 macrophages. Para-
doxically, day 12 macrophages did not display increased phos-
phorylation of p38 MAPK, MK2, and RipK1. Rather, we
observed that in day 12 macrophages, the phosphorylation of
p38 MAPK, MK2, and RipK1 was reduced in response to BP
treatment, without any impairment in TNF expression.
Reduced phosphorylation of RipK1 in day 12 macrophages
could be due to reduced MK2 phosphorylation in these cells.
Our results indicate that although the activation of the p38
MAPK/MK2pathway is reduced in differentiatedmacrophages
during ripoptosome signaling, inhibition of the p38 MAPK/
MK2 pathway abrogates their resistance to ripoptosome-in-
duced cell death. The mechanism of this paradox remains
unclear, but our observations should strengthen the view that
the p38/MK2 pathway directly or indirectly inhibits RipK1-de-
pendent cell death. It is important to note that XIAP-deficient
macrophages displayed enhanced TNF production and MK2
activation, which also supports the notion of complex cross-
talk between p38/MK2 and XIAP.
We have recently reported that the K45Amutation of RipK1
reduces cell death, reactive oxygen species production, and
caspase-8 activation during infection of macrophages with
S. enterica Typhimurium, impairing S. enterica Typhimurium
control invivo (30).RipK1promotescaspase-8–dependentapo-
ptosis or RipK3-dependent necroptosis in macrophages in
response to Yersinia infection (63). These results reveal the key
role of ripoptosome signaling in promoting bacterial control,
and any impairment in this pathway may lead to compromised
control of infection. On the other hand, in sterile inflammatory
diseases, RipK1 might have detrimental effects. An inhibitor of
RipK1, Nec-1, has been shown to have a protective role during
ischemia-induced injury (64–68). Because RipK1 is the central
component of the ripoptosome complex, there have been spec-
ulations that RipK1might be playing a critical role in the patho-
genesis of these diseases through ripoptosome, rather than
necrosome, signaling (69).We have revealed here amechanism
whereby long-lived macrophages resist cell death due to
increased expression of XIAP, which would allow them to con-
tinue expressing high levels of inflammatory cytokines and
resist pathogen attack. On the other hand, newly differentiat-
ing/infiltrating macrophages may produce less inflammatory
cytokines and turn overmore quickly to aid pathogen clearance
and return to homeostasis. Whereas XIAP-deficient mice do
not show any obvious developmental abnormality (70), muta-
tions in humanXIAP result in immunodeficiencywith aberrant
activation of myeloid cells (71). These results further reinforce
the role of ripoptosome signaling in human diseases.
Experimental procedures
Mice
C57BL/6J (stock no. 0664), TNF-R1,2/ (stock no. 03243),
TNF-R1/ (stock no. 03242), TNF-R2/ (stock no. 02620),
TNF/ (stock no. 05540), Trif-mutant (stock no. 05037),
Myd88/ (stock no. 09088), and NIK/ (stock no. 025557)
were obtained from Jackson Laboratory. RipK1K45A were
obtained from Dr. Peter J. Gough (GSK, Philadelphia, PA),
RipK3/ were obtained from Dr. Visva Dixit (Genentech),
MK2/ were obtained from Dr. Matthias Gaestel (Hannover
Medical School),XIAP/were obtained fromDr. Robert Kor-
neluk (Children’s Hospital of Eastern Ontario), and Ifnar1/
were obtained from Dr. Kaja Murali Krishna (Emory Univer-
sity, Atlanta, GA). Mice were maintained at the animal facility
of the University of Ottawa, Faculty of Medicine. All proce-
dures were approved by the uOttawa Animal Care Committee.
Cell isolation, cell culture, and viability measurements
Monocytes were purified from the bonemarrow using beads
obtained from StemCell Technologies (Vancouver, Canada).
Macrophages were generated frommouse bone marrow as per
our previously published procedures (28). For in vivo macro-
phage activation, 1 ml of 3% thioglycolate solution was injected
into the peritoneal cavity of mice, and cells were isolated at day
5. Peritoneal macrophages were purified by staining cells with
anti-mouse F4/80-PE followed by capture with anti-PE beads
from StemCell Technologies. Macrophages were plated in
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96-well flat-bottomed plate (Falcon). Cells (7  104 cells/well)
were seeded and incubated overnight. Different small-molecule
inhibitors and agonists were added to cells. Following treat-
ment with appropriate concentrations of inhibitors and ago-
nists, cells were usually left for 24 h, unless otherwise indicated,
and cell viability was measured by various assays. Cell viability
was measured by MTT uptake or by propidium iodide (PI)/
Hoechst staining (28, 72). MTT was obtained from Sigma-Al-
drich (M5655). Absorbance of the dye was measured at 570 nm
using a filterMax plate reader (Molecular Devices). Hoechst
was obtained from Invitrogen Inc. (catalog no. 33342) and used
at a concentration of 2.5. PI was obtained from BD Biosciences
(catalog no. 550825) and used at a 1:10 dilution. Cell viability
was measured by imaging cells under an AxioObserver D1
microscope, and the AxioVision release 4.8 program was used
to capture and analyze images.
In the case of splenic macrophages, nonfractionated spleen
cells were incubated overnight with various inhibitors and
stimulants. Cells were then stained with anti-F4/80-PE-Cy7,
anti-CD3-eFluor450, anti-CD19-eFluor450, and zombie yellow
fixable viability dye. 180 l of sample was acquired from each
well by a high-throughput sample port, and the number of via-
ble cells in gated macrophages was determined by flow
cytometry.
Inhibitors and reagents
The SMAC mimetic BP (S7015) was obtained from Selleck-
chem (S7015) and used at a concentration of 10M. The SMAC
mimetic BV6 was obtained from Genentech Inc. and also used
at a concentration of 10 M. Ultrapure LPS from Escherichia
coli 055:B5 was obtained from Sigma-Aldrich (L4524) and used
at a concentration of 1 ng/ml, if not indicated otherwise.
Recombinant mouse TNF was obtained from R&D Systems
(410-MT) and used at a concentration of 50 ng/ml. The MEK/
ERK inhibitor PD0325901 (S1036) was obtained from Selleck-
chem and used at a concentration of 20 nM. The JNK inhibitor
SP600125 was obtained from Sigma-Aldrich (S5567) and used
at a concentration of 20 M. Inhibitor of p38 MAPK, rali-
metinib, was obtained from Selleckchem (S1494) and used at a
concentration of 5 M. RipK1 inhibitor, Nec-1, was obtained
from Sigma-Aldrich (catalog no. 9037) and used at a concen-
tration of 10 M. RipK3 inhibitor, GSK872, was obtained from
Glixx (GLXC-03990) and used at a concentration of 5M. Pan-
caspase inhibitor (Z-VAD-fmk, A1902) and caspase-8 inhibitor
(Z-IETD-fmk, B3232) were obtained from ApexBio (A1902)
and used at a concentration of 50 M. Caspase-3 inhibitor
(z-DEVD-FMK, FMK004) and caspase-9 inhibitor (zLEHD-
FMK, FMK008) were obtained from R&D Systems and used at
a concentration of 50 M. The following inhibitors against
NF-B were used: JSH-23 (CAS749886-87-1, Calbiochem),
Ly2409881 (S7697, Selleckchem), and TPCA-1 (S2824, Selleck-
chem). These were used at a concentration of 1–5 M.
Western blotting
Macrophages were seeded in a 24-well plate at 3 105 cells/
well and treated with inhibitors or agonists. At various time
intervals, cells were washed with cold PBS and lysed in cold 1%
SDS lysis buffer with 1% -mercaptoethanol. Samples were
boiled immediately and frozen. Lysates were run on a 1.5-mm
15-well 8, 10, 12, or 15% polyacrylamide gel, depending on the
size of the proteins of interest. Gels were run at 130 V for 1 h. A
polyvinylidene difluoridemembranewas soaked in 100%meth-
anol and washed with the transfer buffer, and then the transfer
was run at 100 V for 1 h. Membrane was blocked in 5% skim
milk in Tris-buffered saline solution (TBS: 0.5 M Tris, 1.5 NaCl,
pH 7) with 0.5% Tween 20 (TBST) or 5% BSA. The following
primary antibodieswere used forWestern blotting:mouse anti-
RipK1 (BD Biosciences, catalog no. 610459), rabbit anti-RipK3
(ProSci Inc., catalog no. 2283), mouse anti--actin (BD Biosci-
ences, catalog no. 612656), rabbit anti-cIAP1/2 (Cyclex,
CY-P1040), rabbit anti-p38 MAPK (Cell Signaling, catalog no.
8690), rabbit anti-phospho-p38 MAPK (Cell Signaling, catalog
no. 4511), rat anti-caspase-8 (Enzo, ADI-AAM-212-E), rabbit
anti-XIAP (Cell Signaling, catalog no. 2042), rabbit anti-cFLIPL
(Santa Cruz Biotechnology, Inc., sc-8347), rabbit anti-MK2
(Cell Signaling, catalog no. 3007), rabbit anti-phospho MK2
(Cell Signaling, catalog no. 3042), rabbit anti-ERK1/2 (Cell Sig-
naling, catalog no. 4695), rabbit anti-phospho-ERK1/2 (Cell
Signaling, catalog no. 4370), rabbit anti-JNK (Cell Signaling,
catalog no. 9252), and rabbit anti-phospho-JNK (Cell Signaling,
catalog no. 4668). Primary antibodies were diluted in appropri-
ate blocking buffer (5%milk or BSA), added to themembrane in
a sealed plastic pouch, and incubated overnight on the shaker at
4 °C. Membranes were then washed with TBST before adding
secondary antibody diluted in the appropriate blocking buffer
(5% milk or BSA). Membranes were washed and visualized
using either luminol ECL substrate (Thermo Scientific, catalog
no. 32106) or West Femto ECL substrate (Thermo Scientific,
catalog no. 34095). Photosensitive film (Sigma-Aldrich, Car-
estream Health, catalog no. 785019) was used to examine pro-
tein expression. Results were quantified using densitometric
analysis. The densitometric quantification of Western blotting
signals was performed using ImageJ version 1.48 software.
Flow cytometry
Cells were washed with staining buffer (1% BSA in PBS).
FcBlock (anti-CD16/32) (BD Biosciences, catalog no. 553142)
was added to the cells in the staining buffer and incubated for 10
min at 4 °C. Various flurophore-conjugated antibodies were
added in the staining buffer. Cells were protected from the light
and incubated with the antibodies for 30min at 4 °C. After that,
cells were washed with the staining buffer and resuspended in
flow fixative (PBS containing 1% paraformaldehyde and 0.02%
sodium azide). Samples were then acquired on a CyAN-ADP
analyzer (Beckman Coulter) or LSR-Fortessa or FACSCelesta
(BD Biosciences) and analyzed using Kaluza software (Beck-
man Coulter, version 1.2) or FlowJo version 10 (FlowJo). The
following antibodies were obtained from eBiosciences: anti-
mouse Ly-6C-PE (12-5932-82), anti-mouse CD11b-Pe-Cy7
(2500112-81), anti-mouse Ly-6G-FITC (11-5931-82), and anti-
mouse F4/80-APC-Cy7 (47-4801-80).
Caspase bioassays
Thecaspase-8,caspase-9,andcaspase-3/7activitiesweremea-
sured by using the caspase-Glo 8 (Promega, G8200), caspase-
Glo 9 (Promega, G8210), and caspase-Glo 3/7 (Promega,
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G8090) luminescent kits. The substrate was mixed with the
buffer, and the mix was added to the cells in the 96-well plates.
The luminescence generated in the wells was measured using a
FilterMaxTM F5 plate reader (Molecular Devices).
Immunoprecipitation
Cell lysates were immunoprecipitated with a Dynabeads
co-immunoprecipitation kit (Invitrogen, Life Technologies,
14321D, Burlington, Canada) with rat anti-caspase-8 (ENZO,
1G12). The caspase-8 antibody was coupled with the Dyna-
beadswith incubation at 37 °C overnight and thenwashingwith
various buffers. The next day, bone marrow–derived macro-
phages were treated with birinapant for 4 h. Then the cells were
washed with ice-cold 1 PBS and lysed in immunoprecipita-
tion lysis buffer. The lysates were sonicated for 10 s and then
centrifuged at 5000 g for 5 min at 4 °C to remove large debris
and nuclei. 10l of the supernatant was stored as input, and the
remaining clarified lysate was then incubated with antibody-
coupled Dynabeads for 16–24 h at 4 °C on a rocker platform.
The unbound fractions were saved at 20 °C, and the bound
proteins were eluted. 10 l of the 4 SDS-loading dye was
added to the eluent and boiled for 5 min. The final eluent was
analyzed by Western blotting.
Cytokine production
Cytokine expression by macrophages was measured in the
supernatant at 24 h post-stimulation with LPS (100 ng/ml). In
case of cells stimulated with BP, the level of TNF was too low
to be detected by ELISA. In this case, TNF expression was
measured by the WEHI-164 cell bioassay (73).
Statistics
All error bars show S.E. Unpaired two-tailed student’s t
test or one-way analysis of variance followed by a Bonferroni
post hoc test was used to determine statistical significance.
All statistical analyses were performed using GraphPad
Prism software.
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